Onkologie. 2021:15(4):169-173 | DOI: 10.36290/xon.2021.033

Skin toxicity of BRAF and MEK inhibitors

Miroslav Důra
Dermatovenerologická klinika 1. LF UK a VFN, Praha

Inhibitors of mutated BRAF kinase together with inhibitors of MEK kinase serve as one of alternative ways in modern systemic treatment of metastatic melanoma. BRAF and MEK inhibitors also demonstrated effect in adjuvant setting. Nevertheless, these drugs reveal a specific range of adverse reactions, skin toxicity being one of the most frequent and highly specific for certain drug combinations. The article summarizes different types of skin toxicity focused on etiopathogenetic mechanisms, grading and management.

Keywords: BRAF inhibitor, MEK inhibitor, skin, toxicity, photosensitivity, exanthema, therapy.

Published: September 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Důra M. Skin toxicity of BRAF and MEK inhibitors. Onkologie. 2021;15(4):169-173. doi: 10.36290/xon.2021.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hagen B, Trinh VA. Managing side effects of vemurafenib therapy for advanced melanoma. J Adv Pract Oncol. 2014; 5(6): 400-10. Go to original source...
    2. Kichenadasse G, Hughes JH, Fahmy A, Rowland A, Sorich MJ, Hopkins AH. Relationship between apparent systemic clearance of vemurafenib and toxicity in patients with melanoma. J Clin Pharmacol. 2021 Apr 27. doi: 10.1002/jcph.1882. Epub ahead of print. PMID: 33908053. Go to original source... Go to PubMed...
    3. Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, Vogel A, Zimmer L, Gutzmer R. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019; 4(3): e000491. Go to original source... Go to PubMed...
    4. Hopkins AM, Rathod AD, Rowland A, Kichenadasse G, Sorich MJ. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials. BMC Cancer. 2020; 20(1): 157. Go to original source... Go to PubMed...
    5. Piraccini BM, Patrizi A, Fanti PA, Starace M, Bruni F, Melotti B, Misciali C, Dika E. RASopathic alopecia: hair changes associated with vemurafenib therapy. J Am Acad Dermatol. 2015; 72(4): 738-41. Go to original source... Go to PubMed...
    6. Mathea S, Abdul Azeez KR, Salah E, Tallant C, Wolfreys F, Konietzny R, Fischer R, Lou HJ, Brennan PE, Schnapp G, Pautsch A, Kessler BM, Turk BE, Knapp S. Structure of the human protein kinase ZAK in complex with vemurafenib. ACS Chem Biol. 2016; 11(6): 1595-602. Go to original source...
    7. Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, Sperandi F, Piraccini BM. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol. 2016; 26(3): 232-239. Go to original source... Go to PubMed...
    8. McClenahan P, Lin LL, Tan JM, Flewell-Smith R, Schaider H, Jagirdar K, Atkinson V, Lambie D, Prow TW, Sturm RA, Soyer HP. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. JAMA Dermatol. 2014; 150: 1079-1082. Go to original source... Go to PubMed...
    9. Satoh TK, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer HD, Rordorf T, Maul JT, Hafner J, Navarini AA, Contassot E, French LE. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020; 130(3): 1417-1430. Go to original source... Go to PubMed...
    10. Piroth M, Frénard C, Eugène-Lamer J, Dreno B, Quéreux G. Hypodermite sous inhibiteur de BRAF et/ou inhibiteur de MEK: revue de la littérature à partir d'une nouvelle observation. Ann Dermatol Venereol. 2020; 147(12): 833-841. Go to original source... Go to PubMed...
    11. Yilmaz M, Celik U, Hascicek S. Radiation recall dermatitis with dabrafenib and trametinib: A case report. World J Clin Cases. 2020; 8(3): 522-526. Go to original source... Go to PubMed...
    12. Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). J Eur Acad Dermatol Venereol. 2021; 35(3): 607-614. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.